Intensity Therapeutics
INTS
14 hedge funds and large institutions have $1.06M invested in Intensity Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 25 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.62% more ownership
Funds ownership: 6.52% → 7.15% (+0.62%)
33% less capital invested
Capital invested by funds: $1.58M → $1.06M (-$524K)
60% less funds holding
Funds holding: 35 → 14 (-21)
76% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCNMGF
Nano-Cap New Millennium Growth Fund
Staten Island,
New York
|
+$204K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.1K |
| 3 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$33.3K |
| 4 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
+$28.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Legacy Advisors
Plymouth Meeting,
Pennsylvania
|
-$62.9K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$58.7K |
| 3 |
State Street
Boston,
Massachusetts
|
-$55.9K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$53.3K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
-$41K |
INTS Hedge Fund Activity: Q1 2026 in Review
14 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q1 2026, worth a combined $1.06M — down 33% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of INTS and 6 opened new positions — a net loss of 19 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Nano-Cap New Millennium Growth Fund, opening a new position worth an estimated $204K. The largest seller was Legacy Advisors, exiting entirely with an estimated $62.9K sold.
- 14 institutional investors held Intensity Therapeutics (INTS) as of Q1 2026, down from 35 in Q4 2025.
- Funds reported $1.06M of Intensity Therapeutics stock for Q1 2026, down 33% quarter-over-quarter.
- 6 funds opened new Intensity Therapeutics positions in Q1 2026 and 25 closed out, a net change of -19 holders.
- The largest Intensity Therapeutics buyer in Q1 2026 was Nano-Cap New Millennium Growth Fund, an estimated $204K added.
- The largest Intensity Therapeutics seller in Q1 2026 was Legacy Advisors, an estimated $62.9K sold.
Based on aggregated 13F filings for Q1 2026.